Description

Indication

Dosage

In the phase 2 clinical trial VCL-HB01 was given as an intramuscular injection once every 28 days for a total of 4 doses

Updates

February 25, 2019 Recruitment Status of the Phase 2 clinical trial was updated to reflect the Study Status as completed and no IPDSharing.

June 11, 2018, Vical announced their Phase 2 study did not meet its primary endpoint of annualized lesion recurrence rate calculated based on those genital recurrences that were both clinically- and virologically-confirmed during a minimum of nine months of surveillance.

The Company reported that there was significantly less power to show the vaccine effect compared to a placebo effect in this trial.

Vical terminated their HSV-2 program after announcing the Phase 2 study results.